Lyme & Associated Diseases Alliance

Created by Dr. Richard Horowitz

MSIDS-style Lyme and co-infection planning

The MSIDS model created by Dr. Richard Horowitz treats chronic Lyme presentations as multi-factorial illness rather than a single-organ problem. The practical value for an alliance website is a structured checklist: infections, immune dysfunction, inflammation, toxins, allergies, sleep, hormones, nutrition, mitochondria, autonomic dysfunction, psychiatric symptoms, pain, and social stressors.

1. Map the drivers. Identify Borrelia, Babesia, Bartonella, anaplasma/ehrlichia, viral reactivation, Candida, mold/mycotoxin exposure, MCAS, POTS, pain generators, sleep apnea, endocrine disruption, and deficiencies.
2. Prioritize co-infection clues. Babesia patterns often include sweats, air hunger, and hemolysis markers. Bartonella patterns can include neuropathic pain, lymph-node symptoms, striae-like rashes, ocular or neuropsychiatric flares.
3. Use layered treatment cautiously. Antimicrobial combinations, anti-parasitic therapy, anti-inflammatory support, detoxification, and immune support should be sequenced with safety labs and medication-interaction review.
4. Reserve advanced protocols for specialists. Published dapsone-combination approaches associated with Horowitz require careful screening, G6PD assessment, CBC/CMP monitoring, methemoglobin awareness, folate-family support, and clinician experience. They are not public self-treatment plans.
5. Reassess every cycle. Use a symptom score, function score, adverse-event log, and clear stop rules. If function is not improving, revisit the diagnosis rather than simply adding more agents.

Bartonella care discussion

Bartonella pathway to discuss with an LLMD

Bartonella-focused clinical care often treats the illness as persistent, vascular, neurologic, inflammatory, and difficult to confirm with one simple test. For LADA patients, the practical goal is to recognize the pattern, document it clearly, and connect with an LLMD who understands Bartonella evaluation and monitored combination therapy.

1. Look for the pattern. Foot-sole pain, shin pain, nerve pain, striae-like streaks, swollen lymph nodes, eye irritation, headaches, neuropsychiatric flares, insomnia, rage/anxiety shifts, POTS-like symptoms, and vascular or connective-tissue symptoms can support a Bartonella discussion.
2. Use better testing strategy. Account for Bartonella henselae, B. quintana, and other species; serology limits; PCR timing; enrichment culture options; blood-smear clues; and repeat testing when paired with clinical pattern recognition.
3. Discuss combination therapy only with supervision. Bartonella care is often discussed around intracellular and biofilm-aware combinations, such as rifamycin-class agents paired with macrolide, tetracycline, or other clinician-selected agents. These require prescription oversight, interaction review, liver/CBC monitoring, pregnancy screening where relevant, and clear stop rules.
4. Protect the patient during treatment. LLMDs may need to address MCAS, histamine reactions, GI tolerance, sleep, autonomic dysfunction, psychiatric safety, detoxification tolerance, and medication sensitivity before or during Bartonella treatment.
5. Track response, not just symptoms. Patients should track function, neuropathy, mood/sleep shifts, POTS symptoms, pain migration, rashes, medication reactions, and relapse cycles so the clinician can adjust safely.

Neil Nathan-informed

The sensitive patient mold and toxin pathway

Neil Nathan's work is especially useful for patients who flare from ordinary doses, supplements, binders, antimicrobials, fragrances, foods, or stress. The model begins with tolerance, not intensity.

For patients whose mold/CIRS or MCAS-like symptoms overlap with nasal colonization questions, see the nasal colonization subsection and the full mold and nasal colonization guide.

1. Stabilize first. Address sleep, limbic-system threat response, vagal tone, pain, MCAS/histamine symptoms, constipation, hydration, and electrolyte stability before pushing detoxification.
2. Find the exposure. Mold avoidance and remediation decisions come before binders. A patient who remains in a water-damaged environment may not tolerate treatment.
3. Start low and slow. Binders, antifungals, antimicrobial herbs, prescription antimicrobials, sauna, and methylation support can all provoke reactions in sensitive patients.
4. Separate intolerance from failure. A flare may mean dose, sequence, drainage, mast cells, or exposure load is wrong, rather than the whole plan being wrong.
5. Build resilience. Gentle movement, nervous-system retraining, nutrition, trauma-informed care, and pacing can improve tolerance for later infection or toxin treatment.

Andrew W. Campbell, MD

Campbell-informed mold and mycotoxin pathway

Dr. Andrew Campbell's work is included as a major mold and mycotoxin perspective for clinician discussion. His framework emphasizes identifying and correcting exposure, using MyMycoLab serum IgG and IgE antibody testing in context, considering supervised antifungal treatment in selected cases, and supporting recovery with targeted nutrition and monitoring.

1. Start with exposure control. Document water intrusion, dampness, visible or hidden mold, HVAC concerns, symptom changes away from the building, and whether remediation corrected the moisture source.
2. Discuss MyMycoLab testing carefully. Campbell's testing model uses blood-serum IgG and IgE antibody patterns related to mycotoxin targets. These results do not prove the location of mold colonization or replace a full clinical evaluation.
3. Review antifungal risk before treatment. Campbell-associated materials discuss prolonged itraconazole in selected patients. This requires prescriber supervision, liver monitoring, cardiac and drug-interaction review, and clear stop rules.
4. Layer support cautiously. Targeted supplements, diet changes, gut support, and monitoring may be discussed, but the combination should not be treated as a public self-treatment protocol.
5. Keep the evidence balanced. Campbell's work is important in the mold toxicity/CIRS space, but some interpretations remain debated and should be weighed with conventional mold, allergy, asthma, sinus, and environmental-health guidance.

For the full Campbell protocol summary and source discussion, open the Mold and CIRS protocol section or the Dr. Andrew Campbell source materials.

Shoemaker-informed

CIRS protocol structure for mold and biotoxin illness

The Shoemaker protocol is a named, sequential approach to chronic inflammatory response syndrome after exposure to water-damaged buildings and other biotoxins. It is best treated as a trained-clinician protocol, with objective testing and strict attention to exposure control.

1. Confirm exposure and susceptibility. Use building history, ERMI or HERTSMI-2 style environmental data when appropriate, symptom clusters, VCS screening, and HLA/molecular markers as guided by a trained clinician.
2. Leave or remediate exposure. Protocol success depends on reducing ongoing exposure before expecting durable improvement.
3. Bind biotoxins safely. Cholestyramine or colesevelam are commonly discussed in Shoemaker care, but require prescription oversight, timing away from medications, constipation prevention, and lipid/liver review.
4. Address nasal reservoirs and inflammation. Nasal colonization evaluation, inflammatory markers, endocrine markers, coagulation, complement, and immune dysregulation may shape next steps.
5. Consider VIP only after criteria are met. Vasoactive intestinal peptide is a late-stage Shoemaker consideration, not a front-line experiment.

Alliance model

A patient appointment planning arc

Directed symptom control

Symptomatic therapy: targeted relief that supports the recovery arc

Targeted symptom management can make the difference between a patient who can maintain restorative therapy and one who cannot. Symptomatic therapies are best used temporarily while the foundation is rebuilt.

1. Pain and inflammation. Curcumin (turmeric), omega-3 fatty acids, boswellia, and low-dose naltrexone (LDN) are clinician-discussed options for everyday inflammation and pain. NSAIDs are used sparingly due to gut and kidney load.
2. Sleep support. Melatonin, passionflower, magnesium glycinate, and good sleep hygiene are first-line considerations. Sleep is when the glymphatic system clears brain toxins and the immune system resets.
3. Anxiety and mood. Adaptogens, CBD, 5-HTP, GABA-supportive nutrients, and cranial electrotherapy stimulation (CES) are options some LLMDs discuss with appropriate patients. Medications should be reviewed for interactions.
4. Mast cell and histamine support. Quercetin, vitamin C, stinging nettle, and DAO enzyme supplements are common starting points for histamine intolerance and MCAS-like reactivity.
5. Gi and motility. Digestive enzymes, bitters, ginger, and targeted probiotics help stabilize digestion so oral medications and supplements are better tolerated.

Advanced interventions

Heroic therapy: intensive options for resistant cases under close supervision

Heroic therapies are the interventions most patients think of first — antibiotics, antiparasitics, intensive protocols. They have a place but work best after the restorative foundation is stable enough to tolerate them.

1. Prescription antimicrobials. Doxycycline, rifampin, azithromycin, dapsone-combination therapy (DDDCT/HDDCT), tafenoquine-based Babesia care, and other prescription agents require strict clinician monitoring, lab safety, and stop rules.
2. Herbal antimicrobial intensification. Some LLMDs layer concentrated herbal tinctures (cryptolepis, sida acuta, houttuynia, artemisinin, Samento, Banderol) alongside or between prescription cycles.
3. Biofilm disruption. Enzymes such as lumbrokinase, nattokinase, serrapeptase, and interfase are discussed for disrupting protective biofilm matrices so that antimicrobials can reach persistent microbes.
4. Hyperthermia and sauna. Far-infrared sauna raises core temperature and supports detoxification; whole-body hyperthermia is a more intensive clinician-supervised option in selected cases.
5. Peptide therapy and immune modulators. Thymic peptides, BPC-157, and other immune-modulating peptides are emerging tools discussed in specialist LLMD settings.

* Heroic therapies carry higher risk. They belong with a clinician who can monitor labs, interactions, psychiatric safety, and organ stress. They are not self-directed treatment plans. *

Foundation of tolerance

Gut restoration: the gateway to medication tolerance and immune balance

A large share of the immune system resides in the gut. If digestion, absorption, and microbial balance are disrupted, oral therapies cannot work effectively and medication intolerance limits options.

1. Eliminate dietary triggers. Remove gluten, dairy, sugar, processed foods, and known food sensitivities to reduce systemic inflammation and gut irritation.
2. Support digestive function. Betaine HCl with pepsin, digestive enzymes, and bitter herbs support proper breakdown and absorption of nutrients and medications.
3. Heal the mucosal lining. L-glutamine, zinc carnosine, aloe vera, marshmallow root, and deglycyrrhizinated licorice (DGL) help repair the integrity of the gut barrier.
4. Restore microbial balance. Targeted probiotics (Lactobacillus, Bifidobacterium, Saccharomyces boulardii), prebiotic fibers, and fermented foods rebuild a healthy intestinal microbiome.
5. Address constipation and motility. Magnesium, vitamin C, hydration, and gentle prokinetic support prevent toxin reabsorption and improve tolerance of oral therapies.

Why microbes persist

Biofilm: the protective matrix that makes stealth microbes hard to reach

Biofilms are colonies of microbes (bacteria, viruses, protozoa, fungi) embedded in a protective matrix. Inside biofilms, microbes can resist both the immune system and antimicrobial agents.

1. Borrelia forms biofilm-like colonies. Research shows Borrelia burgdorferi can form biofilm aggregates that resist antibiotics and immune clearance. Bartonella and Babesia also use biofilm and intracellular persistence strategies.
2. Biofilm disruptors are a clinical tool. Enzymatic agents (lumbrokinase, nattokinase, serrapeptase) and herbal biofilm breakers (monolaurin, stevia, xylitol, oregano oil) are discussed by LLMDs to expose embedded microbes.
3. Timing matters. Biofilm disruption is typically sequenced after the patient is stable enough to tolerate the release of microbes and toxins that follows.
4. Not all biofilm is harmful. Beneficial biofilms in the colon protect the intestinal lining. The goal is targeted disruption of pathogenic biofilms, not blanket elimination.